Christian Klein, Distinguished Scientist is Head of Oncology Programs at the Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Switzerland specialized in the discovery, validation and preclinical development of antibody based cancer immunotherapies and bispecific antibodies. During his >14 years at Roche he has made major contributions as research project leader to the development and FDA/EMA approval of GAZYVA/GAZYVARO (obinutuzumab, GA101), the preclinical development of four bispecific antibodies currently in active clinical development: 1) CEA-IL2v immunocytokine RG7813 (Ph I), 2) anti-Ang-2/VEGF CrossMAb RG7221 in oncology (Ph II), 3) anti-VEGF/Ang-2 CrossMAb RG7716 in ophthalmology (Ph I) and 4) CEA-CD3 T cell bispecific antibody RG7802 (Ph I), as well as the development of Roche’s novel proprietary bispecific antibody platforms e.g. the CrossMAb technology.
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October
To sponsor or exhibit contact:
Derek Cavanagh
+44 (0)207 092 1297
derek.cavanagh@terrapinn.com
To speak:
Joan Shutt
+44 (0)207 092 1134
joan.shutt@terrapinn.com